What biotechnology is chasing billions of dollars?

Globally, more capital began to “run wild” in the biomedical field: Last year, the top 25 companies in the global pharmaceutical R&D expenditure invested a total of 100.441 billion US dollars for research and development; global biomedical field venture capital, listing financing, mergers and acquisitions total It reached a record high of US$224.8 billion. The health care industry has become the most active area of ​​global venture capital. The number of transactions per year ranks first in all industries, and the transaction amount ranks second. What biotechnology are these capitals chasing?

Bio big data calculates health

Wan Gang, vice chairman of the National Committee of the Chinese People's Political Consultative Conference and Minister of Science and Technology, pointed out at the 2015 International Bio-Economic Conference held on July 23 this year that the application of big data and cloud computing technology can deeply explore the explosive growth of massive life science data and promote the foundation. The deep integration of research, clinical applications, health records and other sources of data, subverting the traditional life sciences research and development model, to lay a solid foundation for the realization of " precise medical " and "smart health."

Currently, the world is actively deploying bio big data. For example, the Global Alliance was formed to promote genomic and clinical data sharing; the National Institutes of Health budget for 2014 supports big data research, launches the Big Data Center of Excellence program, launches the microbiological cloud program; Europe launches a new clinical trial database; The Institute of Health Information, the backbone of the Bioinformatics Technology Center, and the British Pharmaceutical Industry Association have also proposed big data roadmaps.

Dong Zhifeng, deputy director of the China Biotechnology Development Center, said, "Life science has entered the era of big data and big platforms, and will completely change the way of life of human beings. For example, the era of the thousand-yuan genome is coming, applied to prenatal testing, disease testing, and personalization. Drugs, etc., make personalized medicine based on gene diagnosis based on gene diagnosis a new model of disease treatment."

The world's innovative enterprises have accelerated their pace to develop new products around the “Thousand Yuan Genome”. Edico Genom of the United States has developed a gene sequencing chip that can reduce the time to analyze a genome from 24 hours to 18 minutes, and save $6 million by analyzing 18,000 genomes in 4 years.

Chinese enterprises are not falling behind. This year, Huada Gene launched a super-sequencer and a desktop high-throughput sequencer to realize the localization of the sequencer, breaking the situation that China's gene sequencing equipment is subject to people. The "Super Sequencer" Revolocity sequencing system can complete 10,000 whole genome sequencing in one year and will increase to 30,000 per year, surpassing all existing sequencing solutions. The desktop sequencer bgiseq-500 automates sample preparation, sequencing and data analysis for one-click operation in a variety of inspection applications. At the same time, based on its latest large database, Huada Gene selected 2855 of the 14 most common genetic diseases, and launched a self-developed prenatal genetic testing product, smarttesttm, which can cover an average of 90%. The above pathogenic mutations.

As biotechnology and information technology get closer, it will be easier for people to understand why IT companies have “squeezed” bio-economic express trains in the past two years. Google’s risk investment in health care and life sciences in 2014 reached $425 million, more than one-third of its total venture capital, compared to just 9% in 2013. Apple launched the ResearchKit medical research platform, which allows researchers to use the open source architecture to develop and design a variety of medical applications, collect health data for a variety of patients, and promote the participation of patients and researchers in medical research, changing the way medical personnel access data. .

Interdisciplinary crosses to find more solutions

Despite the rapid development of biotechnology, 90% of the more than 4,500 diseases are still in jeopardy. These innovative propositions without “solutions” are difficult to obtain through traditional R&D ideas and methods, and can only rely on multiple cross-disciplines to seek answers.

In the cross of disciplines in the field of biotechnology, the United States is fast. The Massachusetts Institute of Technology published an article in 2011 - "The Third Revolution: Life Sciences, Physical Science and Engineering Society." In May 2014, the National Academy of Sciences issued a report, "Convergence: Promoting Interdisciplinary Integration in the Fields of Life Science, Natural Science, and Engineering." The National Science Foundation, the National Cancer Institute, the Anti-Cancer Organization, and the Fifth Foundation for Cancer Research, jointly investing $11.5 million in convergent cancer research, using a imaginative laboratory model that integrates new approaches from physics and mathematics to Helps understand the complex dynamic disease of cancer.

"Currently, life sciences, physics, information science, engineering and other disciplines tend to cross disciplines. This cross-integration accelerates the development of emerging technologies, making people's understanding of life more comprehensive, accurate, quantitative, and visual. The handling is improved." Dong Zhifeng said.

Emerging technologies that have been born out of disciplines are numerous. For example, optogenetics technology is a new technology produced by the combination of genetic technology and light control technology. It can be used not only for the study of advanced complex neural activities, but also for clinical treatment. This technology is expected to be applied to patients with blindness due to retinopathy, making it look good again. As a "sweet" in the neuroscience community, this technology has been used in many brain laboratories for brain science research. For example, molecular imaging combines molecular biochemistry, data processing, nanotechnology, image processing and other technologies to enable real-time, in vivo and continuous observation of physiological processes at the cellular and molecular levels during disease development and progression, to achieve early warning of disease, Early diagnosis and treatment evaluation.

The cross-disciplinary integration further promotes the innovation and development of related technologies, which in turn leads to industrial changes in the field of biomedicine in China. Dong Zhifeng said that in bio-agriculture, biological breeding has developed rapidly, bio-fertilizer has great potential for development, and bio-pesticide industry has grown rapidly. In medical devices, mobile medical ushered in a market outbreak, and wearable devices will rapidly spread in the next five years. Medical treatment and in vitro diagnostic products are developed in the high-end field; in bio-manufacturing, the construction of high-efficiency artificial cell factories will accelerate the penetration of modern bio-manufacturing into traditional industries and change its existing production mode; in medical services, precision medicine will target patients. The genetic or physiological characteristics of customized treatment programs to achieve personalized treatment; in the pharmaceutical industry, the rapid development of small molecule drugs, biological drugs to provide support for individualized treatment, the internationalization of Chinese medicine is accelerating.

Disposable Tracheostomy Tube Kit

Tracheostomy Tube Kit,tracheostomy tube,pediatric tracheostomy tube 4.5,shiley tracheostomy tube

Anesthesia Medical Co., Ltd. , https://www.medicaldiverse.com